Document
false--12-31Q3201900013560902578229213507746980758111605241332643282806121055805210850995304831332640585000200000000400000000160020466162511940160020466162511940694500042050005222700051900000448000030974000552900002500000066000190000001195200041740000342800014350000P1YP3Y 0001356090 2019-01-01 2019-09-30 0001356090 2019-10-31 0001356090 2018-12-31 0001356090 2019-09-30 0001356090 xon:RelatedPartiesAggregatedMember 2019-09-30 0001356090 xon:RelatedPartiesAggregatedMember 2018-12-31 0001356090 2018-01-01 2018-09-30 0001356090 2019-07-01 2019-09-30 0001356090 us-gaap:ProductMember 2019-07-01 2019-09-30 0001356090 xon:CollaborationandlicensingagreementsMember 2019-01-01 2019-09-30 0001356090 xon:OtherMember 2018-01-01 2018-09-30 0001356090 us-gaap:ProductMember 2019-01-01 2019-09-30 0001356090 us-gaap:ServiceMember 2018-07-01 2018-09-30 0001356090 2018-07-01 2018-09-30 0001356090 us-gaap:ServiceMember 2019-07-01 2019-09-30 0001356090 us-gaap:ProductMember 2018-01-01 2018-09-30 0001356090 xon:CollaborationandlicensingagreementsMember 2018-07-01 2018-09-30 0001356090 us-gaap:ProductMember 2018-07-01 2018-09-30 0001356090 xon:OtherMember 2019-01-01 2019-09-30 0001356090 xon:CollaborationandlicensingagreementsMember 2018-01-01 2018-09-30 0001356090 xon:CollaborationandlicensingagreementsMember 2019-07-01 2019-09-30 0001356090 us-gaap:ServiceMember 2019-01-01 2019-09-30 0001356090 us-gaap:ServiceMember 2018-01-01 2018-09-30 0001356090 xon:OtherMember 2019-07-01 2019-09-30 0001356090 xon:OtherMember 2018-07-01 2018-09-30 0001356090 xon:CollaborationandlicensingagreementsMember xon:RelatedPartiesAggregatedMember 2019-01-01 2019-09-30 0001356090 xon:CollaborationandlicensingagreementsMember xon:RelatedPartiesAggregatedMember 2018-07-01 2018-09-30 0001356090 xon:CollaborationandlicensingagreementsMember xon:RelatedPartiesAggregatedMember 2018-01-01 2018-09-30 0001356090 xon:CollaborationandlicensingagreementsMember xon:RelatedPartiesAggregatedMember 2019-07-01 2019-09-30 0001356090 us-gaap:RetainedEarningsMember 2019-09-30 0001356090 us-gaap:ParentMember 2019-07-01 2019-09-30 0001356090 us-gaap:CommonStockMember 2019-09-30 0001356090 us-gaap:NoncontrollingInterestMember 2019-07-01 2019-09-30 0001356090 us-gaap:CommonStockMember 2019-06-30 0001356090 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001356090 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001356090 us-gaap:RetainedEarningsMember 2019-06-30 0001356090 us-gaap:ParentMember 2019-09-30 0001356090 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001356090 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001356090 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001356090 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001356090 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001356090 us-gaap:NoncontrollingInterestMember 2019-09-30 0001356090 2019-06-30 0001356090 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001356090 us-gaap:NoncontrollingInterestMember 2019-06-30 0001356090 us-gaap:ParentMember 2019-06-30 0001356090 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001356090 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0001356090 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-09-30 0001356090 us-gaap:NoncontrollingInterestMember 2018-12-31 0001356090 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0001356090 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001356090 us-gaap:RetainedEarningsMember 2018-12-31 0001356090 us-gaap:ParentMember 2019-01-01 2019-09-30 0001356090 us-gaap:CommonStockMember 2018-12-31 0001356090 us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0001356090 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0001356090 us-gaap:ParentMember 2018-12-31 0001356090 us-gaap:NoncontrollingInterestMember 2018-09-30 0001356090 us-gaap:ParentMember 2018-01-01 2018-09-30 0001356090 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-09-30 0001356090 us-gaap:NoncontrollingInterestMember 2018-01-01 2018-09-30 0001356090 us-gaap:CommonStockMember 2018-01-01 2018-09-30 0001356090 us-gaap:CommonStockMember 2017-12-31 0001356090 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-09-30 0001356090 2018-09-30 0001356090 us-gaap:NoncontrollingInterestMember 2017-12-31 0001356090 us-gaap:RetainedEarningsMember 2018-09-30 0001356090 us-gaap:CommonStockMember 2018-09-30 0001356090 us-gaap:ParentMember 2017-12-31 0001356090 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001356090 2017-12-31 0001356090 us-gaap:RetainedEarningsMember 2018-01-01 2018-09-30 0001356090 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001356090 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001356090 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0001356090 us-gaap:ParentMember 2018-09-30 0001356090 us-gaap:RetainedEarningsMember 2017-12-31 0001356090 us-gaap:ParentMember 2018-07-01 2018-09-30 0001356090 us-gaap:ParentMember 2018-06-30 0001356090 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001356090 2018-06-30 0001356090 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001356090 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-09-30 0001356090 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0001356090 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0001356090 us-gaap:NoncontrollingInterestMember 2018-07-01 2018-09-30 0001356090 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001356090 us-gaap:CommonStockMember 2018-06-30 0001356090 us-gaap:NoncontrollingInterestMember 2018-06-30 0001356090 us-gaap:RetainedEarningsMember 2018-06-30 0001356090 xon:AquaBountyMember 2019-09-30 0001356090 xon:OragenicsMember 2018-07-01 2018-09-30 0001356090 xon:AquaBountyMember 2019-07-01 2019-09-30 0001356090 xon:AquaBountyMember 2019-09-30 0001356090 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001356090 2019-01-01 2019-03-31 0001356090 xon:AquaBountyMember 2019-01-01 2019-09-30 0001356090 xon:OragenicsMember 2018-01-01 2018-09-30 0001356090 us-gaap:EquityMethodInvestmentsMember 2019-09-30 0001356090 us-gaap:EquityMethodInvestmentsMember 2018-12-31 0001356090 us-gaap:EquityMethodInvestmentsMember 2018-07-01 2018-09-30 0001356090 us-gaap:EquityMethodInvestmentsMember 2019-07-01 2019-09-30 0001356090 us-gaap:EquityMethodInvestmentsMember 2018-01-01 2018-09-30 0001356090 us-gaap:EquityMethodInvestmentsMember 2019-01-01 2019-09-30 0001356090 xon:CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member 2019-09-30 0001356090 xon:CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member 2018-09-01 2018-09-30 0001356090 xon:CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member 2018-09-30 0001356090 xon:ActoBioTherapeuticsInc.Member xon:HarvestIntrexonEnterpriseFundILPMember 2018-09-01 2018-09-30 0001356090 xon:CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member 2018-08-31 0001356090 xon:HarvestIntrexonEnterpriseFundILPMember 2018-09-01 2018-09-30 0001356090 xon:IntrexonT1DPartnersLLCMember xon:CollaborationandlicensingagreementsMember 2016-03-01 2016-03-31 0001356090 xon:IntrexonEnergyPartnersIILLCMember 2015-12-31 0001356090 xon:IntrexonT1DPartnersLLCMember 2018-11-30 0001356090 xon:IntrexonT1DPartnersLLCMember 2018-10-31 0001356090 xon:IntrexonT1DPartnersLLCMember us-gaap:InvestorMember 2016-03-31 0001356090 xon:IntrexonEnergyPartnersIILLCMember xon:CollaborationandlicensingagreementsMember 2015-12-01 2015-12-31 0001356090 xon:IntrexonEnergyPartnersMember 2019-09-30 0001356090 xon:IntrexonEnergyPartnersIILLCMember us-gaap:InvestorMember 2015-12-31 0001356090 xon:IntrexonEnergyPartnersIILLCMember xon:OtherAccruedLiabilitiesMember 2019-09-30 0001356090 xon:IntrexonEnergyPartnersIILLCMember xon:OtherAccruedLiabilitiesMember 2018-12-31 0001356090 xon:IntrexonEnergyPartnersMember us-gaap:InvestorMember 2014-03-31 0001356090 xon:IntrexonEnergyPartnersMember xon:OtherAccruedLiabilitiesMember 2019-09-30 0001356090 xon:IntrexonEnergyPartnersMember 2014-03-31 0001356090 xon:IntrexonT1DPartnersLLCMember 2018-11-01 2018-11-30 0001356090 xon:IntrexonT1DPartnersLLCMember 2016-03-31 0001356090 xon:EnviroFlightLLCMember xon:InvestmentsInAffiliatesMember 2018-12-31 0001356090 xon:IntrexonEnergyPartnersIILLCMember us-gaap:InvestorMember 2015-12-01 2015-12-31 0001356090 xon:IntrexonEnergyPartnersMember xon:CollaborationandlicensingagreementsMember 2014-03-01 2014-03-31 0001356090 xon:IntrexonT1DPartnersLLCMember us-gaap:InvestorMember 2016-03-01 2016-03-31 0001356090 xon:IntrexonEnergyPartnersMember us-gaap:InvestorMember 2014-03-01 2014-03-31 0001356090 xon:IntrexonEnergyPartnersIILLCMember xon:AllInvestorsMember 2015-12-01 2015-12-31 0001356090 xon:EnviroFlightLLCMember 2016-03-01 2019-09-30 0001356090 xon:EnviroFlightLLCMember xon:InvestmentsInAffiliatesMember 2019-09-30 0001356090 xon:IntrexonEnergyPartnersMember xon:OtherAccruedLiabilitiesMember 2018-12-31 0001356090 xon:EnviroFlightLLCMember us-gaap:InvestorMember 2016-03-01 2019-09-30 0001356090 xon:FibrocellMember xon:UpfrontAndMilestonePaymentsMember 2018-12-31 0001356090 xon:OtherCollaborationsMember xon:UpfrontAndMilestonePaymentsMember 2018-12-31 0001356090 xon:PerseaBioLLCMember xon:UpfrontAndMilestonePaymentsMember 2018-12-31 0001356090 xon:UpfrontAndMilestonePaymentsMember 2018-12-31 0001356090 xon:IntrexonEnergyPartnersMember xon:UpfrontAndMilestonePaymentsMember 2019-10-01 2019-09-30 0001356090 xon:ZiopharmMember xon:UpfrontAndMilestonePaymentsMember 2019-10-01 2019-09-30 0001356090 xon:ZiopharmMember xon:UpfrontAndMilestonePaymentsMember 2018-12-31 0001356090 xon:SurterraMember 2019-10-01 2019-09-30 0001356090 xon:GenopaverLLCMember xon:UpfrontAndMilestonePaymentsMember 2018-12-31 0001356090 xon:HarvestStartUpEntitiesAggregatedMember xon:UpfrontAndMilestonePaymentsMember 2019-10-01 2019-09-30 0001356090 xon:IntrexonEnergyPartnersIILLCMember xon:UpfrontAndMilestonePaymentsMember 2018-12-31 0001356090 xon:PerseaBioLLCMember xon:UpfrontAndMilestonePaymentsMember 2019-10-01 2019-09-30 0001356090 xon:OragenicsMember xon:UpfrontAndMilestonePaymentsMember 2019-10-01 2019-09-30 0001356090 xon:PerseaBioLLCMember 2019-10-01 2019-09-30 0001356090 xon:HarvestStartUpEntitiesAggregatedMember 2019-10-01 2019-09-30 0001356090 xon:FibrocellMember xon:UpfrontAndMilestonePaymentsMember 2019-10-01 2019-09-30 0001356090 xon:SurterraMember xon:UpfrontAndMilestonePaymentsMember 2019-10-01 2019-09-30 0001356090 xon:IntrexonEnergyPartnersMember 2019-10-01 2019-09-30 0001356090 xon:OragenicsMember xon:UpfrontAndMilestonePaymentsMember 2018-12-31 0001356090 xon:ZiopharmMember 2019-10-01 2019-09-30 0001356090 xon:OtherCollaborationsMember 2019-10-01 2019-09-30 0001356090 xon:SurterraMember xon:UpfrontAndMilestonePaymentsMember 2018-12-31 0001356090 xon:IntrexonEnergyPartnersIILLCMember 2019-10-01 2019-09-30 0001356090 xon:OtherCollaborationsMember xon:UpfrontAndMilestonePaymentsMember 2019-10-01 2019-09-30 0001356090 xon:IntrexonEnergyPartnersMember xon:UpfrontAndMilestonePaymentsMember 2018-12-31 0001356090 xon:IntrexonEnergyPartnersIILLCMember xon:UpfrontAndMilestonePaymentsMember 2019-10-01 2019-09-30 0001356090 xon:FibrocellMember 2019-10-01 2019-09-30 0001356090 xon:OragenicsMember 2019-10-01 2019-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember 2019-10-01 2019-09-30 0001356090 xon:HarvestStartUpEntitiesAggregatedMember xon:UpfrontAndMilestonePaymentsMember 2018-12-31 0001356090 xon:GenopaverLLCMember 2019-10-01 2019-09-30 0001356090 xon:GenopaverLLCMember xon:UpfrontAndMilestonePaymentsMember 2019-10-01 2019-09-30 0001356090 xon:SurterraMember srt:MaximumMember 2019-06-01 2019-06-30 0001356090 xon:FibrocellMember xon:CollaborationandlicensingagreementsMember 2019-01-01 2019-09-30 0001356090 xon:FibrocellMember 2019-04-01 2019-04-30 0001356090 xon:SurterraMember xon:CollaborationandlicensingagreementsMember 2019-06-01 2019-06-30 0001356090 xon:SurterraMember xon:CollaborationandlicensingagreementsMember 2019-01-01 2019-09-30 0001356090 xon:IntrexonEnergyPartnersIILLCMember xon:CollaborationandlicensingagreementsMember 2018-07-01 2018-09-30 0001356090 xon:OragenicsMember xon:CollaborationandlicensingagreementsMember 2019-01-01 2019-09-30 0001356090 xon:FibrocellMember xon:CollaborationandlicensingagreementsMember 2018-07-01 2018-09-30 0001356090 xon:HarvestStartUpEntitiesAggregatedMember xon:CollaborationandlicensingagreementsMember 2018-01-01 2018-09-30 0001356090 xon:IntrexonT1DPartnersLLCMember xon:CollaborationandlicensingagreementsMember 2019-01-01 2019-09-30 0001356090 xon:GenopaverLLCMember xon:CollaborationandlicensingagreementsMember 2018-01-01 2018-09-30 0001356090 xon:GenopaverLLCMember xon:CollaborationandlicensingagreementsMember 2019-01-01 2019-09-30 0001356090 xon:OtherMember xon:CollaborationandlicensingagreementsMember 2019-01-01 2019-09-30 0001356090 xon:OragenicsMember xon:CollaborationandlicensingagreementsMember 2018-01-01 2018-09-30 0001356090 xon:PerseaBioLLCMember xon:CollaborationandlicensingagreementsMember 2019-07-01 2019-09-30 0001356090 xon:PerseaBioLLCMember xon:CollaborationandlicensingagreementsMember 2018-07-01 2018-09-30 0001356090 xon:OtherMember xon:CollaborationandlicensingagreementsMember 2018-07-01 2018-09-30 0001356090 xon:ZiopharmMember xon:CollaborationandlicensingagreementsMember 2018-07-01 2018-09-30 0001356090 xon:AresTradingS.A.Member xon:CollaborationandlicensingagreementsMember 2018-01-01 2018-09-30 0001356090 xon:HarvestStartUpEntitiesAggregatedMember xon:CollaborationandlicensingagreementsMember 2019-01-01 2019-09-30 0001356090 xon:AresTradingS.A.Member xon:CollaborationandlicensingagreementsMember 2019-07-01 2019-09-30 0001356090 xon:ZiopharmMember xon:CollaborationandlicensingagreementsMember 2019-07-01 2019-09-30 0001356090 xon:OragenicsMember xon:CollaborationandlicensingagreementsMember 2018-07-01 2018-09-30 0001356090 xon:GenopaverLLCMember xon:CollaborationandlicensingagreementsMember 2019-07-01 2019-09-30 0001356090 xon:OragenicsMember xon:CollaborationandlicensingagreementsMember 2019-07-01 2019-09-30 0001356090 xon:AresTradingS.A.Member xon:CollaborationandlicensingagreementsMember 2019-01-01 2019-09-30 0001356090 xon:ZiopharmMember xon:CollaborationandlicensingagreementsMember 2019-01-01 2019-09-30 0001356090 xon:HarvestStartUpEntitiesAggregatedMember xon:CollaborationandlicensingagreementsMember 2018-07-01 2018-09-30 0001356090 xon:PerseaBioLLCMember xon:CollaborationandlicensingagreementsMember 2018-01-01 2018-09-30 0001356090 xon:AresTradingS.A.Member xon:CollaborationandlicensingagreementsMember 2018-07-01 2018-09-30 0001356090 xon:SurterraMember xon:CollaborationandlicensingagreementsMember 2018-01-01 2018-09-30 0001356090 xon:FibrocellMember xon:CollaborationandlicensingagreementsMember 2019-07-01 2019-09-30 0001356090 xon:IntrexonT1DPartnersLLCMember xon:CollaborationandlicensingagreementsMember 2019-07-01 2019-09-30 0001356090 xon:IntrexonEnergyPartnersMember xon:CollaborationandlicensingagreementsMember 2018-07-01 2018-09-30 0001356090 xon:IntrexonEnergyPartnersIILLCMember xon:CollaborationandlicensingagreementsMember 2019-01-01 2019-09-30 0001356090 xon:SurterraMember xon:CollaborationandlicensingagreementsMember 2019-07-01 2019-09-30 0001356090 xon:OtherMember xon:CollaborationandlicensingagreementsMember 2019-07-01 2019-09-30 0001356090 xon:IntrexonEnergyPartnersMember xon:CollaborationandlicensingagreementsMember 2019-07-01 2019-09-30 0001356090 xon:SurterraMember xon:CollaborationandlicensingagreementsMember 2018-07-01 2018-09-30 0001356090 xon:IntrexonEnergyPartnersMember xon:CollaborationandlicensingagreementsMember 2018-01-01 2018-09-30 0001356090 xon:IntrexonEnergyPartnersMember xon:CollaborationandlicensingagreementsMember 2019-01-01 2019-09-30 0001356090 xon:ZiopharmMember xon:CollaborationandlicensingagreementsMember 2018-01-01 2018-09-30 0001356090 xon:IntrexonEnergyPartnersIILLCMember xon:CollaborationandlicensingagreementsMember 2019-07-01 2019-09-30 0001356090 xon:OtherMember xon:CollaborationandlicensingagreementsMember 2018-01-01 2018-09-30 0001356090 xon:IntrexonEnergyPartnersIILLCMember xon:CollaborationandlicensingagreementsMember 2018-01-01 2018-09-30 0001356090 xon:HarvestStartUpEntitiesAggregatedMember xon:CollaborationandlicensingagreementsMember 2019-07-01 2019-09-30 0001356090 xon:PerseaBioLLCMember xon:CollaborationandlicensingagreementsMember 2019-01-01 2019-09-30 0001356090 xon:IntrexonT1DPartnersLLCMember xon:CollaborationandlicensingagreementsMember 2018-01-01 2018-09-30 0001356090 xon:GenopaverLLCMember xon:CollaborationandlicensingagreementsMember 2018-07-01 2018-09-30 0001356090 xon:FibrocellMember xon:CollaborationandlicensingagreementsMember 2018-01-01 2018-09-30 0001356090 xon:IntrexonT1DPartnersLLCMember xon:CollaborationandlicensingagreementsMember 2018-07-01 2018-09-30 0001356090 xon:PrepaidProductAndServiceRevenuesMember 2019-09-30 0001356090 xon:CollaborationandlicensingagreementsMember 2019-09-30 0001356090 xon:DeferredRevenueOtherMember 2019-09-30 0001356090 xon:PrepaidProductAndServiceRevenuesMember 2018-12-31 0001356090 xon:CollaborationandlicensingagreementsMember 2018-12-31 0001356090 xon:DeferredRevenueOtherMember 2018-12-31 0001356090 us-gaap:CertificatesOfDepositMember 2018-12-31 0001356090 us-gaap:USGovernmentDebtSecuritiesMember 2018-12-31 0001356090 us-gaap:CertificatesOfDepositMember 2019-09-30 0001356090 us-gaap:USGovernmentDebtSecuritiesMember 2019-09-30 0001356090 us-gaap:FairValueInputsLevel3Member 2019-01-01 2019-09-30 0001356090 us-gaap:FairValueInputsLevel3Member 2019-09-30 0001356090 us-gaap:FairValueInputsLevel3Member 2018-12-31 0001356090 xon:A3.5ConvertibleNotesDue2023Member 2018-12-31 0001356090 xon:A3.5ConvertibleNotesDue2023Member 2019-09-30 0001356090 us-gaap:FairValueInputsLevel1Member 2019-09-30 0001356090 us-gaap:FairValueInputsLevel3Member xon:OtherFinancialAssetsMember 2019-09-30 0001356090 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentDebtSecuritiesMember 2019-09-30 0001356090 xon:OtherFinancialAssetsMember 2019-09-30 0001356090 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentDebtSecuritiesMember 2019-09-30 0001356090 us-gaap:FairValueInputsLevel3Member us-gaap:EquitySecuritiesMember 2019-09-30 0001356090 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentDebtSecuritiesMember 2019-09-30 0001356090 us-gaap:FairValueInputsLevel1Member us-gaap:EquitySecuritiesMember 2019-09-30 0001356090 us-gaap:FairValueInputsLevel2Member 2019-09-30 0001356090 us-gaap:EquitySecuritiesMember 2019-09-30 0001356090 us-gaap:FairValueInputsLevel1Member xon:OtherFinancialAssetsMember 2019-09-30 0001356090 us-gaap:FairValueInputsLevel2Member us-gaap:EquitySecuritiesMember 2019-09-30 0001356090 us-gaap:FairValueInputsLevel2Member xon:OtherFinancialAssetsMember 2019-09-30 0001356090 us-gaap:FairValueInputsLevel3Member xon:OtherFinancialAssetsMember 2018-12-31 0001356090 us-gaap:FairValueInputsLevel2Member us-gaap:EquitySecuritiesMember 2018-12-31 0001356090 us-gaap:FairValueInputsLevel1Member us-gaap:EquitySecuritiesMember 2018-12-31 0001356090 us-gaap:EquitySecuritiesMember 2018-12-31 0001356090 xon:OtherFinancialAssetsMember 2018-12-31 0001356090 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentDebtSecuritiesMember 2018-12-31 0001356090 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentDebtSecuritiesMember 2018-12-31 0001356090 us-gaap:FairValueInputsLevel3Member us-gaap:EquitySecuritiesMember 2018-12-31 0001356090 us-gaap:FairValueInputsLevel1Member 2018-12-31 0001356090 us-gaap:FairValueInputsLevel1Member xon:OtherFinancialAssetsMember 2018-12-31 0001356090 us-gaap:FairValueInputsLevel2Member 2018-12-31 0001356090 us-gaap:FairValueInputsLevel2Member xon:OtherFinancialAssetsMember 2018-12-31 0001356090 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentDebtSecuritiesMember 2018-12-31 0001356090 xon:SuppliesEmbryosAndOtherProductionMaterialsMember 2018-12-31 0001356090 xon:LivestockMember 2018-12-31 0001356090 xon:LivestockMember 2019-09-30 0001356090 xon:SuppliesEmbryosAndOtherProductionMaterialsMember 2019-09-30 0001356090 xon:FeedMember 2018-12-31 0001356090 xon:FeedMember 2019-09-30 0001356090 xon:WorkInProcessMember 2019-09-30 0001356090 xon:WorkInProcessMember 2018-12-31 0001356090 us-gaap:TrademarksMember 2018-12-31 0001356090 us-gaap:CustomerRelationshipsMember 2018-12-31 0001356090 us-gaap:IntellectualPropertyMember 2018-12-31 0001356090 us-gaap:InProcessResearchAndDevelopmentMember 2018-12-31 0001356090 us-gaap:InProcessResearchAndDevelopmentMember 2019-09-30 0001356090 us-gaap:IntellectualPropertyMember 2019-09-30 0001356090 us-gaap:TrademarksMember 2019-09-30 0001356090 us-gaap:CustomerRelationshipsMember 2019-09-30 0001356090 xon:A3.5ConvertibleNotesDue2023Member 2019-07-01 2019-09-30 0001356090 xon:A3.5ConvertibleNotesDue2023Member 2019-01-01 2019-09-30 0001356090 xon:A3.5ConvertibleNotesDue2023Member 2018-07-01 2018-09-30 0001356090 xon:A3.5ConvertibleNotesDue2023Member 2018-01-01 2018-09-30 0001356090 xon:OtherLongTermDebtMember 2018-12-31 0001356090 xon:OtherLongTermDebtMember 2019-09-30 0001356090 us-gaap:ConvertibleDebtMember 2018-12-31 0001356090 us-gaap:NotesPayableToBanksMember 2019-09-30 0001356090 us-gaap:NotesPayableToBanksMember 2018-12-31 0001356090 us-gaap:ConvertibleDebtMember 2019-09-30 0001356090 xon:TransOvaGeneticsLcMember us-gaap:RevolvingCreditFacilityMember xon:FirstNationalBankofOmahaMember 2019-09-30 0001356090 xon:A3.5ConvertibleNotesDue2023Member 2018-07-31 0001356090 xon:ActoBioTherapeuticsInc.Member xon:HarvestIntrexonEnterpriseFundILPMember us-gaap:ConvertibleDebtMember 2019-07-01 2019-09-30 0001356090 xon:ExemplarGeneticsLLCMember us-gaap:RevolvingCreditFacilityMember xon:AmericanStateBankMember 2019-09-30 0001356090 srt:MinimumMember xon:A3.5ConvertibleNotesDue2023Member 2018-07-01 2018-07-31 0001356090 xon:TransOvaGeneticsLcMember xon:AmericanStateBankMember us-gaap:NotesPayableToBanksMember 2019-09-30 0001356090 xon:A3.5ConvertibleNotesDue2023Member 2018-07-01 2018-07-31 0001356090 xon:MerckConvertibleNoteMember 2018-12-31 0001356090 srt:MaximumMember xon:A3.5ConvertibleNotesDue2023Member 2018-07-01 2018-07-31 0001356090 xon:TransOvaGeneticsLcMember xon:AmericanStateBankMember us-gaap:NotesPayableToBanksMember 2019-01-01 2019-09-30 0001356090 xon:TransOvaGeneticsLcMember us-gaap:RevolvingCreditFacilityMember xon:FirstNationalBankofOmahaMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-01-01 2019-09-30 0001356090 xon:ActoBioTherapeuticsInc.Member xon:HarvestIntrexonEnterpriseFundILPMember us-gaap:ConvertibleDebtMember 2018-09-30 0001356090 xon:TransOvaGeneticsLcMember srt:MinimumMember us-gaap:RevolvingCreditFacilityMember xon:FirstNationalBankofOmahaMember 2019-09-30 0001356090 xon:MerckConvertibleNoteMember 2018-12-01 2018-12-31 0001356090 xon:ActoBioTherapeuticsInc.Member xon:HarvestIntrexonEnterpriseFundILPMember us-gaap:ConvertibleDebtMember 2019-09-30 0001356090 xon:ActoBioTherapeuticsInc.Member xon:HarvestIntrexonEnterpriseFundILPMember us-gaap:ConvertibleDebtMember 2018-07-01 2018-09-30 0001356090 xon:ActoBioTherapeuticsInc.Member xon:HarvestIntrexonEnterpriseFundILPMember us-gaap:ConvertibleDebtMember 2018-01-01 2018-09-30 0001356090 xon:ActoBioTherapeuticsInc.Member xon:HarvestIntrexonEnterpriseFundILPMember us-gaap:ConvertibleDebtMember 2019-01-01 2019-09-30 0001356090 us-gaap:DomesticCountryMember 2018-07-01 2018-09-30 0001356090 us-gaap:ForeignCountryMember 2019-07-01 2019-09-30 0001356090 us-gaap:ForeignCountryMember 2018-01-01 2018-09-30 0001356090 us-gaap:DomesticCountryMember 2019-07-01 2019-09-30 0001356090 us-gaap:ForeignCountryMember 2019-01-01 2019-09-30 0001356090 us-gaap:DomesticCountryMember 2018-01-01 2018-09-30 0001356090 us-gaap:ForeignCountryMember 2018-07-01 2018-09-30 0001356090 us-gaap:ForeignCountryMember 2019-09-30 0001356090 us-gaap:DomesticCountryMember 2019-09-30 0001356090 xon:GeneratedAfter2017Member 2019-09-30 0001356090 us-gaap:DomesticCountryMember 2019-01-01 2019-09-30 0001356090 us-gaap:AccumulatedTranslationAdjustmentMember 2019-09-30 0001356090 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0001356090 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-09-30 0001356090 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0001356090 2018-07-31 0001356090 xon:AquaBountyMember 2018-10-01 2018-10-31 0001356090 2018-01-01 2018-01-31 0001356090 2018-07-01 2018-07-31 0001356090 xon:AquaBountyMember 2018-01-01 2018-01-31 0001356090 xon:AffiliatesOfThirdSecurityMember 2018-01-01 2018-01-31 0001356090 xon:AquaBountyMember 2019-03-01 2019-03-31 0001356090 xon:AquaBountyMember 2018-01-01 2018-01-31 0001356090 xon:AquaBountyMember 2018-10-01 2018-10-31 0001356090 xon:IntrexonStockOptionPlanMember 2018-12-31 0001356090 xon:IntrexonStockOptionPlanMember 2019-01-01 2019-09-30 0001356090 xon:IntrexonStockOptionPlanMember 2019-09-30 0001356090 xon:IntrexonStockOptionPlanMember 2018-01-01 2018-12-31 0001356090 xon:IntrexonStockOptionPlan2008PlanMember 2013-08-31 0001356090 xon:IntrexonStockOptionPlan2013PlanMember 2019-09-30 0001356090 us-gaap:SellingGeneralAndAdministrativeExpensesMember srt:ChiefExecutiveOfficerMember 2018-01-01 2018-09-30 0001356090 srt:ChiefExecutiveOfficerMember 2019-01-01 2019-09-30 0001356090 xon:IntrexonStockOptionPlan2019PlanMember 2019-09-30 0001356090 xon:IntrexonStockOptionPlan2008PlanMember 2019-09-30 0001356090 us-gaap:SellingGeneralAndAdministrativeExpensesMember srt:ChiefExecutiveOfficerMember 2019-01-01 2019-09-30 0001356090 us-gaap:SellingGeneralAndAdministrativeExpensesMember srt:ChiefExecutiveOfficerMember 2019-07-01 2019-09-30 0001356090 us-gaap:SellingGeneralAndAdministrativeExpensesMember srt:ChiefExecutiveOfficerMember 2018-07-01 2018-09-30 0001356090 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2019-09-30 0001356090 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0001356090 xon:CostOfProductsMember 2018-01-01 2018-09-30 0001356090 xon:CostOfServicesMember 2019-01-01 2019-09-30 0001356090 xon:CostOfProductsMember 2019-01-01 2019-09-30 0001356090 xon:CostOfProductsMember 2018-07-01 2018-09-30 0001356090 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-09-30 0001356090 xon:CostOfServicesMember 2019-07-01 2019-09-30 0001356090 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-09-30 0001356090 us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2018-09-30 0001356090 xon:CostOfServicesMember 2018-07-01 2018-09-30 0001356090 xon:CostOfProductsMember 2019-07-01 2019-09-30 0001356090 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-07-01 2018-09-30 0001356090 xon:CostOfServicesMember 2018-01-01 2018-09-30 0001356090 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-09-30 0001356090 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0001356090 srt:MaximumMember 2019-01-01 2019-09-30 0001356090 srt:MinimumMember 2019-01-01 2019-09-30 0001356090 xon:LicensingAndPatentInfringementSuitMember 2016-02-01 2019-03-31 0001356090 xon:XYLLCMember xon:LicensingAndPatentInfringementSuitMember 2016-04-01 2016-04-30 0001356090 xon:XYLLCMember xon:LicensingAndPatentInfringementSuitMember 2019-01-01 2019-09-30 0001356090 xon:LicensingAndPatentInfringementSuitMember 2016-01-01 2016-12-31 0001356090 xon:XYLLCMember xon:LicensingAndPatentInfringementSuitMember 2019-09-30 0001356090 xon:LicensingAndPatentInfringementSuitMember 2019-01-01 2019-09-30 0001356090 xon:LicensingAndPatentInfringementSuitMember 2004-01-01 2016-04-30 0001356090 xon:LicensingAndPatentInfringementSuitMember 2016-04-01 2016-04-30 0001356090 xon:XYLLCMember xon:LicensingAndPatentInfringementSuitMember 2019-02-28 0001356090 xon:LicensingAndPatentInfringementSuitMember 2016-04-30 0001356090 xon:XYLLCMember xon:LicensingAndPatentInfringementSuitMember 2019-03-01 2019-03-31 0001356090 xon:FibrocellMember 2017-03-01 2017-03-31 0001356090 xon:ZiopharmMember 2016-06-30 0001356090 xon:ThirdSecurityMember 2019-01-01 2019-09-30 0001356090 xon:ThirdSecurityMember 2019-07-01 2019-09-30 0001356090 us-gaap:PreferredStockMember xon:OragenicsMember 2019-01-01 2019-09-30 0001356090 xon:ThirdSecurityMember us-gaap:CommonStockMember 2015-11-01 2015-11-30 0001356090 xon:FibrocellMember 2017-03-01 2017-03-31 0001356090 us-gaap:PreferredStockMember xon:OragenicsMember 2017-11-01 2017-11-30 0001356090 xon:ThirdSecurityMember 2018-07-01 2018-09-30 0001356090 xon:FibrocellMember 2017-03-31 0001356090 xon:ZiopharmMember 2018-07-01 2018-09-30 0001356090 xon:ZiopharmMember 2018-01-01 2018-09-30 0001356090 us-gaap:PreferredStockMember xon:OragenicsMember 2019-09-30 0001356090 us-gaap:OtherNoncurrentAssetsMember us-gaap:PreferredStockMember xon:FibrocellMember 2018-12-31 0001356090 xon:ThirdSecurityMember 2018-01-01 2018-09-30 0001356090 xon:HistogenicsCorporationOvaScienceInc.andSyntheticBiologicsInc.Member 2018-01-01 2018-09-30 0001356090 us-gaap:OtherNoncurrentAssetsMember us-gaap:PreferredStockMember xon:FibrocellMember 2019-09-30 0001356090 xon:ThirdSecurityMember srt:ChiefExecutiveOfficerMember 2019-09-30 0001356090 us-gaap:OtherNoncurrentAssetsMember xon:ConvertibleNoteandWarrantsMember xon:FibrocellMember 2019-09-30 0001356090 xon:ZiopharmMember 2016-06-01 2016-06-30 0001356090 xon:ZiopharmMember 2016-06-01 2016-06-30 0001356090 xon:ThirdSecurityMember 2015-11-01 2015-11-30 0001356090 us-gaap:OtherNoncurrentAssetsMember xon:ConvertibleNoteandWarrantsMember xon:FibrocellMember 2018-12-31 0001356090 xon:HistogenicsCorporationOvaScienceInc.andSyntheticBiologicsInc.Member 2018-01-01 2018-12-31 0001356090 us-gaap:PreferredStockMember xon:OragenicsMember 2018-12-31 0001356090 us-gaap:WarrantMember 2018-01-01 2018-09-30 0001356090 us-gaap:ConvertibleDebtMember 2018-01-01 2018-09-30 0001356090 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-09-30 0001356090 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-09-30 0001356090 us-gaap:StockOptionMember 2018-01-01 2018-09-30 0001356090 us-gaap:ConvertibleDebtMember 2019-01-01 2019-09-30 0001356090 us-gaap:StockOptionMember 2019-01-01 2019-09-30 0001356090 us-gaap:WarrantMember 2019-01-01 2019-09-30 0001356090 us-gaap:ConvertibleDebtMember 2018-07-01 2018-09-30 0001356090 us-gaap:RestrictedStockUnitsRSUMember 2018-07-01 2018-09-30 0001356090 us-gaap:ConvertibleDebtMember 2019-07-01 2019-09-30 0001356090 us-gaap:RestrictedStockUnitsRSUMember 2019-07-01 2019-09-30 0001356090 us-gaap:StockOptionMember 2018-07-01 2018-09-30 0001356090 us-gaap:WarrantMember 2019-07-01 2019-09-30 0001356090 us-gaap:WarrantMember 2018-07-01 2018-09-30 0001356090 us-gaap:StockOptionMember 2019-07-01 2019-09-30 0001356090 xon:FineChemicalsSegmentMember 2019-01-01 2019-09-30 0001356090 us-gaap:IntersegmentEliminationMember xon:TransOvaSegmentMember 2019-01-01 2019-09-30 0001356090 us-gaap:OperatingSegmentsMember xon:FineChemicalsSegmentMember 2019-01-01 2019-09-30 0001356090 us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001356090 us-gaap:IntersegmentEliminationMember xon:FineChemicalsSegmentMember 2019-01-01 2019-09-30 0001356090 us-gaap:IntersegmentEliminationMember us-gaap:AllOtherSegmentsMember 2019-01-01 2019-09-30 0001356090 us-gaap:AllOtherSegmentsMember 2019-01-01 2019-09-30 0001356090 us-gaap:IntersegmentEliminationMember xon:MethaneBioconversionPlatformSegmentMember 2019-01-01 2019-09-30 0001356090 xon:PrecigenSegmentMember 2019-01-01 2019-09-30 0001356090 us-gaap:IntersegmentEliminationMember xon:OkanaganSegmentMember 2019-01-01 2019-09-30 0001356090 us-gaap:OperatingSegmentsMember xon:OkanaganSegmentMember 2019-01-01 2019-09-30 0001356090 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2019-01-01 2019-09-30 0001356090 us-gaap:OperatingSegmentsMember xon:TransOvaSegmentMember 2019-01-01 2019-09-30 0001356090 us-gaap:IntersegmentEliminationMember 2019-01-01 2019-09-30 0001356090 xon:MethaneBioconversionPlatformSegmentMember 2019-01-01 2019-09-30 0001356090 us-gaap:IntersegmentEliminationMember xon:PrecigenSegmentMember 2019-01-01 2019-09-30 0001356090 us-gaap:OperatingSegmentsMember xon:PrecigenSegmentMember 2019-01-01 2019-09-30 0001356090 us-gaap:OperatingSegmentsMember xon:MethaneBioconversionPlatformSegmentMember 2019-01-01 2019-09-30 0001356090 xon:TransOvaSegmentMember 2019-01-01 2019-09-30 0001356090 xon:OkanaganSegmentMember 2019-01-01 2019-09-30 0001356090 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2019-07-01 2019-09-30 0001356090 us-gaap:IntersegmentEliminationMember 2019-07-01 2019-09-30 0001356090 us-gaap:OperatingSegmentsMember xon:TransOvaSegmentMember 2019-07-01 2019-09-30 0001356090 us-gaap:OperatingSegmentsMember xon:FineChemicalsSegmentMember 2019-07-01 2019-09-30 0001356090 us-gaap:OperatingSegmentsMember xon:OkanaganSegmentMember 2019-07-01 2019-09-30 0001356090 xon:FineChemicalsSegmentMember 2019-07-01 2019-09-30 0001356090 us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001356090 us-gaap:OperatingSegmentsMember xon:MethaneBioconversionPlatformSegmentMember 2019-07-01 2019-09-30 0001356090 us-gaap:IntersegmentEliminationMember xon:FineChemicalsSegmentMember 2019-07-01 2019-09-30 0001356090 us-gaap:OperatingSegmentsMember xon:PrecigenSegmentMember 2019-07-01 2019-09-30 0001356090 us-gaap:IntersegmentEliminationMember xon:TransOvaSegmentMember 2019-07-01 2019-09-30 0001356090 xon:MethaneBioconversionPlatformSegmentMember 2019-07-01 2019-09-30 0001356090 xon:TransOvaSegmentMember 2019-07-01 2019-09-30 0001356090 us-gaap:AllOtherSegmentsMember 2019-07-01 2019-09-30 0001356090 us-gaap:IntersegmentEliminationMember xon:MethaneBioconversionPlatformSegmentMember 2019-07-01 2019-09-30 0001356090 xon:PrecigenSegmentMember 2019-07-01 2019-09-30 0001356090 xon:OkanaganSegmentMember 2019-07-01 2019-09-30 0001356090 us-gaap:IntersegmentEliminationMember xon:PrecigenSegmentMember 2019-07-01 2019-09-30 0001356090 us-gaap:IntersegmentEliminationMember xon:OkanaganSegmentMember 2019-07-01 2019-09-30 0001356090 us-gaap:IntersegmentEliminationMember us-gaap:AllOtherSegmentsMember 2019-07-01 2019-09-30 0001356090 xon:OperatingSegmentsAndCorporateNonSegmentMember 2018-01-01 2018-09-30 0001356090 xon:OperatingSegmentsAndCorporateNonSegmentMember 2018-07-01 2018-09-30 0001356090 xon:OperatingSegmentsAndCorporateNonSegmentMember 2019-07-01 2019-09-30 0001356090 xon:EliminationsAndReconcilingItemsMember 2019-01-01 2019-09-30 0001356090 xon:EliminationsAndReconcilingItemsMember 2019-07-01 2019-09-30 0001356090 xon:ReportableSegmentsMember 2019-07-01 2019-09-30 0001356090 xon:ReportableSegmentsMember 2018-01-01 2018-09-30 0001356090 xon:ReportableSegmentsMember 2018-07-01 2018-09-30 0001356090 xon:OperatingSegmentsAndCorporateNonSegmentMember 2019-01-01 2019-09-30 0001356090 xon:EliminationsAndReconcilingItemsMember 2018-01-01 2018-09-30 0001356090 xon:ReportableSegmentsMember 2019-01-01 2019-09-30 0001356090 xon:EliminationsAndReconcilingItemsMember 2018-07-01 2018-09-30 0001356090 us-gaap:NonUsMember 2019-01-01 2019-09-30 0001356090 us-gaap:NonUsMember 2018-01-01 2018-09-30 0001356090 us-gaap:NonUsMember 2018-07-01 2018-09-30 0001356090 us-gaap:NonUsMember 2019-07-01 2019-09-30 0001356090 us-gaap:NonUsMember 2018-12-31 0001356090 us-gaap:NonUsMember 2019-09-30 0001356090 xon:PrecigenSegmentMember 2018-01-01 2018-09-30 0001356090 us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001356090 us-gaap:IntersegmentEliminationMember xon:MethaneBioconversionPlatformSegmentMember 2018-01-01 2018-09-30 0001356090 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2018-01-01 2018-09-30 0001356090 us-gaap:OperatingSegmentsMember xon:PrecigenSegmentMember 2018-01-01 2018-09-30 0001356090 us-gaap:OperatingSegmentsMember xon:FineChemicalsSegmentMember 2018-01-01 2018-09-30 0001356090 us-gaap:IntersegmentEliminationMember us-gaap:AllOtherSegmentsMember 2018-01-01 2018-09-30 0001356090 xon:OkanaganSegmentMember 2018-01-01 2018-09-30 0001356090 us-gaap:IntersegmentEliminationMember xon:FineChemicalsSegmentMember 2018-01-01 2018-09-30 0001356090 xon:TransOvaSegmentMember 2018-01-01 2018-09-30 0001356090 us-gaap:IntersegmentEliminationMember xon:PrecigenSegmentMember 2018-01-01 2018-09-30 0001356090 xon:MethaneBioconversionPlatformSegmentMember 2018-01-01 2018-09-30 0001356090 us-gaap:OperatingSegmentsMember xon:TransOvaSegmentMember 2018-01-01 2018-09-30 0001356090 xon:FineChemicalsSegmentMember 2018-01-01 2018-09-30 0001356090 us-gaap:IntersegmentEliminationMember xon:TransOvaSegmentMember 2018-01-01 2018-09-30 0001356090 us-gaap:OperatingSegmentsMember xon:MethaneBioconversionPlatformSegmentMember 2018-01-01 2018-09-30 0001356090 us-gaap:OperatingSegmentsMember xon:OkanaganSegmentMember 2018-01-01 2018-09-30 0001356090 us-gaap:IntersegmentEliminationMember xon:OkanaganSegmentMember 2018-01-01 2018-09-30 0001356090 us-gaap:IntersegmentEliminationMember 2018-01-01 2018-09-30 0001356090 us-gaap:AllOtherSegmentsMember 2018-01-01 2018-09-30 0001356090 us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001356090 xon:CorporateAndReconcilingItemsMember 2018-01-01 2018-09-30 0001356090 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-09-30 0001356090 xon:CorporateAndReconcilingItemsMember 2018-07-01 2018-09-30 0001356090 xon:CorporateAndReconcilingItemsMember 2019-07-01 2019-09-30 0001356090 us-gaap:OperatingSegmentsMember xon:UpfrontAndMilestonePaymentsMember 2019-01-01 2019-09-30 0001356090 us-gaap:AllOtherSegmentsMember 2018-07-01 2018-09-30 0001356090 xon:CorporateAndReconcilingItemsMember 2019-01-01 2019-09-30 0001356090 us-gaap:IntersegmentEliminationMember 2018-07-01 2018-09-30 0001356090 us-gaap:CorporateNonSegmentMember 2018-07-01 2018-09-30 0001356090 us-gaap:OperatingSegmentsMember xon:UpfrontAndMilestonePaymentsMember 2018-01-01 2018-09-30 0001356090 us-gaap:CorporateNonSegmentMember 2019-07-01 2019-09-30 0001356090 us-gaap:CorporateNonSegmentMember 2018-01-01 2018-09-30 0001356090 us-gaap:OperatingSegmentsMember xon:UpfrontAndMilestonePaymentsMember 2018-07-01 2018-09-30 0001356090 us-gaap:OperatingSegmentsMember xon:UpfrontAndMilestonePaymentsMember 2019-07-01 2019-09-30 0001356090 us-gaap:IntersegmentEliminationMember xon:TransOvaSegmentMember 2018-07-01 2018-09-30 0001356090 us-gaap:OperatingSegmentsMember xon:TransOvaSegmentMember 2018-07-01 2018-09-30 0001356090 us-gaap:IntersegmentEliminationMember xon:OkanaganSegmentMember 2018-07-01 2018-09-30 0001356090 us-gaap:OperatingSegmentsMember xon:FineChemicalsSegmentMember 2018-07-01 2018-09-30 0001356090 xon:MethaneBioconversionPlatformSegmentMember 2018-07-01 2018-09-30 0001356090 xon:PrecigenSegmentMember 2018-07-01 2018-09-30 0001356090 us-gaap:OperatingSegmentsMember xon:MethaneBioconversionPlatformSegmentMember 2018-07-01 2018-09-30 0001356090 us-gaap:IntersegmentEliminationMember xon:MethaneBioconversionPlatformSegmentMember 2018-07-01 2018-09-30 0001356090 xon:TransOvaSegmentMember 2018-07-01 2018-09-30 0001356090 us-gaap:OperatingSegmentsMember xon:OkanaganSegmentMember 2018-07-01 2018-09-30 0001356090 us-gaap:IntersegmentEliminationMember xon:PrecigenSegmentMember 2018-07-01 2018-09-30 0001356090 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2018-07-01 2018-09-30 0001356090 us-gaap:OperatingSegmentsMember xon:PrecigenSegmentMember 2018-07-01 2018-09-30 0001356090 xon:OkanaganSegmentMember 2018-07-01 2018-09-30 0001356090 us-gaap:IntersegmentEliminationMember xon:FineChemicalsSegmentMember 2018-07-01 2018-09-30 0001356090 xon:FineChemicalsSegmentMember 2018-07-01 2018-09-30 0001356090 us-gaap:IntersegmentEliminationMember us-gaap:AllOtherSegmentsMember 2018-07-01 2018-09-30 0001356090 xon:AquaBountyMember srt:ScenarioForecastMember 2019-10-01 2019-12-31 0001356090 xon:AquaBountyMember xon:AffiliatesOfThirdSecurityMember us-gaap:SubsequentEventMember 2019-10-01 2019-10-31 xbrli:shares iso4217:USD xon:segment xon:board_seat iso4217:USD xbrli:shares xbrli:pure xon:reporting_unit xon:day xon:claim
Table of Contents

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2019
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     .
Commission File Number: 001-36042
 INTREXON CORPORATION
(Exact name of registrant as specified in its charter)
 
Virginia
 
26-0084895
 
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification Number)
 
 
 
 
 
 
20374 Seneca Meadows Parkway
 
 
 
Germantown,
Maryland
 
20876
 
(Address of principal executive offices)
 
(Zip Code)
(301) 556-9900
(Registrant's telephone number, including area code) 
N/A
(Former name, former address and former fiscal year, if changed since last report date) 
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which registered
Common Stock, no par value
 
XON
 
Nasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
 
 
Accelerated filer
 
 
 
 
 
Non-accelerated filer
 
 
Smaller reporting company
 
 
 
 
 
Emerging growth company
 
 
 
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  
As of October 31, 2019, 162,682,637 shares of common stock, no par value per share, were outstanding.


Table of Contents

INTREXON CORPORATION
FORM 10-Q
TABLE OF CONTENTS
 
Item No.
 
Page
1.
 
 
 
 
 
 
2.
3.
4.
 
1.
1A.
2.
3.
4.
5.
6.
 
Intrexon®, Trans Ova Genetics®, Oxitec®, Okanagan Specialty Fruits®, EnviroFlight®, ViaGen®, ActoBiotics®, and Design-Build-Test-Learn® are our and/or our affiliates' registered trademarks in the United States and Precigen™, Progentus™, and ActoBio Therapeutics™ are our and/or our affiliates' common law trademarks in the United States. This Quarterly Report on Form 10-Q, or this Quarterly Report, and the information incorporated herein by reference, contain references to trademarks, service marks, and trade names owned by us or other companies. Solely for convenience, trademarks, service marks and trade names referred to in this Quarterly Report and the information incorporated herein, including logos, artwork, and other visual displays, may appear without the ® or ™ symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks, service marks, and trade names. We do not intend our use or display of other companies' trade names, service marks, or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Other trademarks, trade names, and service marks appearing in this Quarterly Report are the property of their respective owners. Unless the context requires otherwise, references in this Quarterly Report to "Intrexon", "we", "us", and "our" refer to Intrexon Corporation.



2

Table of Contents


Special Note Regarding Forward-Looking Statements
This Quarterly Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this Quarterly Report, including statements regarding our strategy, future events, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management, and expected market growth are forward-looking statements. The words "anticipate", "believe", "estimate", "expect", "intend", "may", "plan", "predict", "project", "would", and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about:
 
our strategy and overall approach to our business model;
our efforts to realign our business and our ability to exercise more control and ownership over the development process and commercialization path;
our efforts to hold or generate significant operating capital, including through partnering, potential asset sales, and operating cost reductions;
our ability to successfully enter new markets or develop additional products, including the expected timing and results of investigational studies and preclinical and clinical trials, whether independently or with our collaborators;
our ability to successfully enter into optimal strategic relationships with our subsidiaries and operating companies that we may form in the future;
competition from existing technologies and products or new technologies and products that may emerge;
actual or anticipated variations in our operating results;
our current and future joint ventures, or JVs, exclusive channel collaborations, or ECCs, license agreements and other collaborations;
developments concerning our collaborators and licensees;
actual or anticipated fluctuations in our competitors' or our collaborators' and licensees' operating results or changes in their respective growth rates;
our cash position;
market conditions in our industry;
our ability to protect our intellectual property and other proprietary rights and technologies;
our ability to adapt to changes in laws, regulations and policies;
our ability and the ability of our collaborators and licensees to adapt to changes in laws, regulations and policies and to secure any necessary regulatory approvals to commercialize any products developed by us or under our ECCs, license agreements and JVs;
the ability of our collaborators and licensees to protect our intellectual property and other proprietary rights and technologies;
our ability and the ability of our collaborators and licensees to develop and successfully commercialize products enabled by our technologies;
the rate and degree of market acceptance of any products developed by us, our subsidiaries, a collaborator under an ECC, or through a JV or license under a license agreement;

3

Table of Contents

our ability to retain and recruit key personnel;
the result of litigation proceedings or investigations that we currently face or may face in the future;
our expectations related to the use of proceeds from our public offerings and other financing efforts; and
our estimates regarding expenses, future revenue, capital requirements, and need for additional financing.
Forward-looking statements may also concern our expectations relating to our subsidiaries and other affiliates. We caution you that the foregoing list may not contain all of the forward-looking statements made in this Quarterly Report.
We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Quarterly Report, particularly in Part II, Item 1A. "Risk Factors," that could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, JVs, or investments that we may make.
You should read this Quarterly Report, the documents that we reference in this Quarterly Report, our Annual Report on Form 10-K for the year ended December 31, 2018, the other reports we have filed with the Securities and Exchange Commission, or SEC, and the documents that we have filed as exhibits to our filings with the SEC completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.


4

Table of Contents

PART I. FINANCIAL INFORMATION
Item 1. Consolidated Financial Statements
Intrexon Corporation and Subsidiaries
Consolidated Balance Sheets
(Unaudited) 
(Amounts in thousands, except share data)
September 30,
2019
 
December 31,
2018
Assets
 
 
 
Current assets
 
 
 
Cash and cash equivalents
$
44,428

 
$
102,768

Restricted cash

 
6,987

Short-term investments
45,285

 
119,688

Equity securities
16,320

 
384

Receivables
 
 
 
Trade, net
20,413

 
21,195

Related parties, net
2,588

 
4,129

Other, net
1,970

 
2,754

Inventory
17,295

 
21,447

Prepaid expenses and other
9,033

 
6,131

Total current assets
157,332

 
285,483

Equity securities, noncurrent
6,515

 
1,798

Property, plant and equipment, net
122,706

 
128,874

Intangible assets, net
107,141

 
129,291

Goodwill
147,949

 
149,585

Investments in affiliates
17,487

 
18,859

Right-of-use assets
43,211

 

Other assets
2,564

 
2,287

Total assets
$
604,905

 
$
716,177

The accompanying notes are an integral part of these consolidated financial statements.

5

Table of Contents

Intrexon Corporation and Subsidiaries
Consolidated Balance Sheets
(Unaudited) 
(Amounts in thousands, except share data)
September 30,
2019
 
December 31,
2018
Liabilities and Total Equity
 
 
 
Current liabilities
 
 
 
Accounts payable
$
7,395

 
$
13,420

Accrued compensation and benefits
9,862

 
10,687

Other accrued liabilities
13,664

 
20,620

Deferred revenue, including $4,205 and $6,945 from related parties as of September 30, 2019 and December 31, 2018, respectively
12,764

 
15,554

Lines of credit
569

 
466

Current portion of long-term debt, including $30,974 to related parties as of September 30, 2019
31,433

 
559

Current portion of lease liabilities
6,224

 

Related party payables
44

 
256

Total current liabilities
81,955

 
61,562

Long-term debt, net of current portion, including $25,000 and $55,290 to related parties as of September 30, 2019 and December 31, 2018, respectively
184,034

 
211,235

Deferred revenue, net of current portion, including $51,900 and $52,227 from related parties as of September 30, 2019 and December 31, 2018, respectively
66,360

 
54,210

Lease liabilities, net of current portion
38,182

 

Deferred tax liabilities, net
5,732

 
7,213

Other long-term liabilities
221

 
3,235

Total liabilities
376,484

 
337,455

Commitments and contingencies (Note 16)

 

Total equity
 
 
 
Common stock, no par value, 400,000,000 and 200,000,000 shares authorized as of September 30, 2019 and December 31, 2018, respectively; 162,511,940 and 160,020,466 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively

 

Additional paid-in capital
1,745,177

 
1,722,012

Accumulated deficit
(1,483,654
)
 
(1,330,545
)
Accumulated other comprehensive loss
(33,102
)
 
(28,612
)
Total Intrexon shareholders' equity
228,421

 
362,855

Noncontrolling interests

 
15,867

Total equity
228,421

 
378,722

Total liabilities and total equity
$
604,905

 
$
716,177

The accompanying notes are an integral part of these consolidated financial statements.

6

Table of Contents

Intrexon Corporation and Subsidiaries
Consolidated Statements of Operations
(Unaudited)
 
(Amounts in thousands, except share and per share data)
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
2019
 
2018
 
2019
 
2018
Revenues
 
 
 
 
 
 
 
Collaboration and licensing revenues, including $3,428 and $11,952 from related parties during the three months ended September 30, 2019 and 2018, respectively, and $14,350 and $41,740 during the nine months ended September 30, 2019 and 2018, respectively
$
6,185

 
$
14,324

 
$
21,252

 
$
51,622

Product revenues
5,852

 
6,829

 
18,528

 
23,549

Service revenues
9,924

 
10,414

 
39,707

 
40,379

Other revenues
1,082

 
881

 
2,877

 
1,839

Total revenues
23,043

 
32,448

 
82,364

 
117,389

Operating Expenses
 
 
 
 
 
 
 
Cost of products
8,263

 
8,877

 
25,729

 
28,046

Cost of services
6,550

 
6,449

 
21,860

 
21,127

Research and development
31,480

 
44,885

 
99,060

 
124,072

Selling, general and administrative
24,741

 
38,708

 
79,818

 
112,872

Impairment loss
626

 

 
626

 

Total operating expenses
71,660

 
98,919

 
227,093

 
286,117

Operating loss
(48,617
)
 
(66,471
)
 
(144,729
)
 
(168,728
)
Other Expense, Net
 
 
 
 
 
 
 
Unrealized and realized appreciation (depreciation) in fair value of equity securities and preferred stock, net
(3,068
)
 
(7,287
)
 
2,634

 
(27,565
)
Interest expense
(4,471
)
 
(3,999
)
 
(13,140
)
 
(4,240
)
Interest and dividend income
885

 
6,107

 
3,280

 
17,323

Other income, net
2,772

 
1,452

 
673

 
571

Total other expense, net
(3,882
)
 
(3,727
)
 
(6,553
)
 
(13,911
)
Equity in net loss of affiliates
(1,647
)
 
(2,870
)
 
(5,034
)
 
(9,880
)
Loss before income taxes
(54,146
)
 
(73,068
)
 
(156,316
)
 
(192,519
)
Income tax benefit
512

 
14,322

 
1,615

 
19,535

Net loss
$
(53,634
)
 
$
(58,746
)
 
$
(154,701
)
 
$
(172,984
)
Net loss attributable to the noncontrolling interests

 
1,422

 
1,592

 
4,113

Net loss attributable to Intrexon
$
(53,634
)
 
$
(57,324
)
 
$
(153,109
)
 
$
(168,871
)
Net loss attributable to Intrexon per share, basic and diluted
$
(0.35
)
 
$
(0.44
)
 
$
(1.00
)
 
$
(1.31
)
Weighted average shares outstanding, basic and diluted
154,596,257

 
129,518,989

 
153,770,785

 
128,843,991

The accompanying notes are an integral part of these consolidated financial statements.


7

Table of Contents

Intrexon Corporation and Subsidiaries
Consolidated Statements of Comprehensive Loss
(Unaudited)
 
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
(Amounts in thousands)
2019
 
2018
 
2019
 
2018
Net loss
$
(53,634
)
 
$
(58,746
)
 
$
(154,701
)
 
$
(172,984
)
Other comprehensive income (loss):
 
 
 
 
 
 
 
Unrealized gain (loss) on investments
(25
)
 
(96
)
 
81

 
(94
)
Loss on foreign currency translation adjustments
(4,871
)
 
(914
)
 
(4,560
)
 
(7,207
)
Comprehensive loss
(58,530
)
 
(59,756
)
 
(159,180
)
 
(180,285
)
Comprehensive loss attributable to the noncontrolling interests

 
1,380

 
1,581

 
4,172

Comprehensive loss attributable to Intrexon
$
(58,530
)
 
$
(58,376
)
 
$
(157,599
)
 
$
(176,113
)
The accompanying notes are an integral part of these consolidated financial statements.


8

Table of Contents

Intrexon Corporation and Subsidiaries
Consolidated Statements of Shareholders' and Total Equity
(Unaudited)
 
(Amounts in thousands, except share data)
Common Stock
 
Additional
Paid-in
Capital
 
Accumulated
Other
Comprehensive
Loss
 
Accumulated
Deficit
 
Total
Intrexon
Shareholders'
Equity
 
Noncontrolling
Interests
 
Total
Equity
Shares
 
Amount
 
 
 
 
 
 
Balances at June 30, 2019
161,917,424

 
$

 
$
1,737,449

 
$
(28,206
)
 
$
(1,430,020
)
 
$
279,223

 
$

 
$
279,223

Stock-based compensation expense

 

 
5,423

 

 

 
5,423

 

 
5,423

Shares issued upon vesting of restricted stock units and for exercises of stock options
164,844

 

 
6

 

 

 
6

 

 
6

Shares issued as payment for services
429,672

 

 
2,299

 

 

 
2,299

 

 
2,299

Net loss

 

 

 

 
(53,634
)
 
(53,634
)
 

 
(53,634
)
Other comprehensive loss

 

 

 
(4,896
)
 

 
(4,896
)
 

 
(4,896
)
Balances at September 30, 2019
162,511,940

 
$

 
$
1,745,177

 
$
(33,102
)
 
$
(1,483,654
)
 
$
228,421

 
$

 
$
228,421

(Amounts in thousands, except share data)
Common Stock
 
Additional
Paid-in
Capital
 
Accumulated
Other
Comprehensive
Loss
 
Accumulated
Deficit
 
Total
Intrexon
Shareholders'
Equity
 
Noncontrolling
Interests
 
Total
Equity
Shares
 
Amount
 
 
 
 
 
 
Balances at June 30, 2018
129,421,788

 
$

 
$
1,504,356

 
$
(21,848
)
 
$
(932,756
)
 
$
549,752

 
$
17,389

 
$
567,141

Stock-based compensation expense

 

 
8,097

 

 

 
8,097

 
35

 
8,132

Shares issued upon vesting of restricted stock units and for exercises of stock options
39,281

 

 
141

 

 

 
141

 

 
141

Shares issued as payment for services
204,402

 

 
2,917

 

 

 
2,917

 

 
2,917

Equity component of convertible debt, net of issuance costs and deferred taxes

 

 
36,868

 

 

 
36,868

 

 
36,868

Shares issued pursuant to share lending agreement
7,479,431

 

 

 

 

 

 

 

Net loss

 

 

 

 
(57,324
)
 
(57,324
)
 
(1,422
)
 
(58,746
)
Other comprehensive income (loss)

 

 

 
(1,052
)
 

 
(1,052
)
 
42

 
(1,010
)
Balances at September 30, 2018
137,144,902

 
$

 
$
1,552,379

 
$
(22,900
)
 
$
(990,080
)
 
$
539,399

 
$
16,044

 
$
555,443

The accompanying notes are an integral part of these consolidated financial statements

9

Table of Contents

Intrexon Corporation and Subsidiaries
Consolidated Statements of Shareholders' and Total Equity
(Unaudited)
(Amounts in thousands, except share data)
Common Stock
 
Additional
Paid-in
Capital
 
Accumulated
Other
Comprehensive
Loss
 
Accumulated
Deficit
 
Total
Intrexon
Shareholders'
Equity
 
Noncontrolling
Interests
 
Total
Equity
Shares
 
Amount
 
 
 
 
 
 
Balances at December 31, 2018
160,020,466

 
$

 
$
1,722,012

 
$
(28,612
)
 
$
(1,330,545
)
 
$
362,855

 
$
15,867

 
$
378,722

Stock-based compensation expense

 

 
14,469

 

 

 
14,469

 
69

 
14,538

Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants
796,859

 

 
63

 

 

 
63

 
250

 
313

Shares issued for accrued compensation
150,908

 

 
1,102

 

 

 
1,102

 

 
1,102

Shares issued as payment for services
1,543,707

 

 
7,987

 

 

 
7,987

 

 
7,987

Shares issued in public offerings, net of issuance costs

 

 

 

 

 

 
6,611

 
6,611

Adjustments for noncontrolling interests

 

 
(456
)
 

 

 
(456
)
 
456

 

Deconsolidation of subsidiary

 

 

 

 

 

 
(21,672
)
 
(21,672
)
Net loss

 

 

 

 
(153,109
)
 
(153,109
)
 
(1,592
)
 
(154,701
)
Other comprehensive income (loss)

 

 

 
(4,490
)
 

 
(4,490
)
 
11

 
(4,479
)
Balances at September 30, 2019
162,511,940

 
$

 
$
1,745,177

 
$
(33,102
)
 
$
(1,483,654
)
 
$
228,421

 
$

 
$
228,421

The accompanying notes are an integral part of these consolidated financial statements

10

Table of Contents

Intrexon Corporation and Subsidiaries
Consolidated Statements of Shareholders' and Total Equity
(Unaudited)
(Amounts in thousands, except share data)
Common Stock
 
Additional
Paid-in
Capital
 
Accumulated
Other
Comprehensive
Loss
 
Accumulated
Deficit
 
Total
Intrexon
Shareholders'
Equity
 
Noncontrolling
Interests
 
Total
Equity
Shares
 
Amount
 
 
 
 
 
 
Balances at December 31, 2017
122,087,040

 
$

 
$
1,397,005

 
$
(15,554
)
 
$
(847,820
)
 
$
533,631

 
$
12,914

 
$
546,545

Cumulative effect of adoption of ASC 606

 

 

 
(104
)
 
26,611

 
26,507

 

 
26,507

Stock-based compensation expense

 

 
28,251

 

 

 
28,251

 
89

 
28,340

Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants
66,314

 

 
262

 

 

 
262

 
812

 
1,074

Shares issued as payment for services
612,117

 

 
8,404

 

 

 
8,404

 

 
8,404

Shares and warrants issued in public offerings, net of issuance costs
6,900,000

 

 
82,374

 

 

 
82,374

 
5,616

 
87,990

Equity component of convertible debt, net of issuance costs and deferred taxes

 

 
36,868

 

 

 
36,868

 

 
36,868

Shares issued pursuant to share lending agreement
7,479,431

 

 

 

 

 

 

 

Adjustments for noncontrolling interests

 

 
(785
)
 

 

 
(785
)
 
785

 

Net loss

 

 

 

 
(168,871
)
 
(168,871
)
 
(4,113
)
 
(172,984
)
Other comprehensive loss

 

 

 
(7,242
)
 

 
(7,242
)
 
(59
)
 
(7,301
)
Balances at September 30, 2018
137,144,902

 
$

 
$
1,552,379

 
$
(22,900
)
 
$
(990,080
)
 
$
539,399

 
$
16,044

 
$
555,443

The accompanying notes are an integral part of these consolidated financial statements

11

Table of Contents

Intrexon Corporation and Subsidiaries
Consolidated Statements of Cash Flows
(Unaudited)
 
Nine Months Ended 
 September 30,
(Amounts in thousands)
2019
 
2018
Cash flows from operating activities
 
 
 
Net loss
$
(154,701
)
 
$
(172,984
)
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
 
Depreciation and amortization
18,711

 
25,184

Loss on disposals of assets, net
1,875

 
4,110

Impairment loss
626

 

Write-off of in-process research and development acquired in asset acquisition

 
8,721

Unrealized and realized (appreciation) depreciation on equity securities and preferred stock, net
(2,634
)
 
27,565

Noncash dividend income
(38
)
 
(14,575
)
Amortization of discounts on investments, net
(949
)
 
(275
)
Equity in net loss of affiliates
5,034

 
9,880

Stock-based compensation expense
14,538

 
28,340

Shares issued as payment for services
7,987

 
8,404

Provision for bad debts
787

 
1,597

Accretion of debt discount and amortization of deferred financing costs
6,962

 
2,116

Deferred income taxes
(1,448
)
 
(19,335
)
Other noncash items
3,284

 
635

Changes in operating assets and liabilities:
 
 
 
Receivables:
 
 
 
Trade
241

 
399

Related parties
1,190

 
6,085

Other
462

 
(909
)
Inventory
4,775

 
2,577

Prepaid expenses and other
(4,320
)
 
(511
)
Right-of-use assets
2,593

 

Other assets
(41
)
 
584

Accounts payable
(4,432
)
 
(731
)
Accrued compensation and benefits
535

 
17,561

Other accrued liabilities
(5,651
)
 
1,591

Deferred revenue
5,056

 
(22,993
)
Lease liabilities
(3,680
)
 

Related party payables
38

 
(167
)
Other long-term liabilities
(585
)
 
253

Net cash used in operating activities
(103,785
)
 
(86,878
)
The accompanying notes are an integral part of these consolidated financial statements.

12

Table of Contents

Intrexon Corporation and Subsidiaries
Consolidated Statements of Cash Flows
(Unaudited)

 
Nine Months Ended 
 September 30,